Physiological effects of slow release potassium phosphate for absorptive hypercalciuria: A randomized double-blind trial

Neil A. Breslau, Howard J. Heller, Alfredo A. Reza-Albarrán, Charles Y C Pak

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Purpose: We examined the physiological effects and tolerance of UroPhos- K,|| a slow release neutral form of potassium phosphate (155 mg. phosphate and 8 mEq. potassium per tablet) in patients with absorptive hypercalciuria. Materials and Methods: A total of 31 patients with absorptive hypercalciuria were studied at baseline and after 3 months of treatment with 4 tablets twice daily of UroPhos-K or placebo (identical in appearance) in a prospective randomized, placebo controlled, double-blind trial during a 4-day inpatient study with a daily constant metabolic diet containing 400 mg. calcium, 100 mEq. sodium and 800 mg. phosphate. Results: Treatment with UroPhos-K did not cause significant gastrointestinal side effects, increase fasting serum potassium or phosphorus, or reduce hemoglobin or creatinine clearance. It reduced urinary calcium excretion from 277 ± 72 to 166 ± 43 mg. per day (p <0.001), associated with a reduction in serum 1,25-dihydroxyvitamin D concentration from 50 ± 11 to 42 ± 9 pg./ml. (p <0.001). Indexes of intestinal calcium absorption and markers of bone turnover also decreased modestly. None of these changes was seen in the placebo group. Conclusions: In patients with absorptive hypercalciuria UroPhos-K seems to correct hypercalciuria by a combination of reduced intestinal absorption, bone resorption and improved renal calcium reabsorption. The drug is well tolerated compared to placebo.

Original languageEnglish (US)
Pages (from-to)664-668
Number of pages5
JournalJournal of Urology
Issue number3 I
StatePublished - Sep 1998


  • Calcium
  • Delayed-action preparations
  • Phosphates
  • Randomized controlled trials
  • Urinary calculi

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Physiological effects of slow release potassium phosphate for absorptive hypercalciuria: A randomized double-blind trial'. Together they form a unique fingerprint.

Cite this